C difficile risk
Oral Bioavailability


IV: 600 - 900 mg IV q8h

PO: 300 - 450 mg PO TID - QID

300 mg PO BID x 7 days

MUST confirm GBS is sensitive to clindamycin before use900 mg IV q8h until delivery

900 mg IV once 30 min prior to skin incision (re-dose if blood loss > 1500 mL during procedure)

900 mg IV q8h (in combination with an appropriate beta lactam)

Infuse over 15 minutes

Age 0-4 wk5 mg/kg/dose IV Q12H

Age 0-7 days>7 days5 mg/kg/dose IV Q12H5 mg/kg/dose IV Q8H

Age 0-7 days>7 days5 mg/kg/dose IV Q8H5 mg/kg/dose IV Q6H

All Infants: 5 mg/kg/dose IV Q6H


6 mg/mL

Mix 6mL of D5W with 0.25mL of 150 mg/mL concentration in a 10mL empty sterile vial = 6 mg/mL

150 mg/mL = 24H 6 mg/mL = 24H Refrigerate

No dosage adjustment required

Neonatal: Reduce dose in liver impairment

General Information

  • Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.

  • Skin & soft tissue infections involving susceptible MRSA.

  • Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

  • For decreasing toxin production in toxic shock syndrome.

Pregnancy: Compatible.

Breastfeeding: Compatible.

Monitor for diarrhea.

High risk of Clostridium difficile infection.

Clindamycin may enhance the neuromuscular-blocking effect of neuromuscular-blocking agents.

Antimicrobial class: Lincosamide

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.